← All indications
Leukemia, Myelomonocytic, Juvenile
A leukemia affecting young children characterized by SPLENOMEGALY, enlarged lymph nodes, rashes, and hemorrhages. Traditionally classed as a myeloproliferative disease, it is now considered a mixed myeloproliferative-mylelodysplastic disorder.
Drugs by status
Phase 4 trials (2)
Phase 3 trials (11)
Phase 2 trials (31)
- azacitidine
- methylprednisolone
- allogeneic natural killer cells
- plerixafor
- blinatumomab
- clofarabine
- etanercept
- tacrolimus
- naltrexone
- trametinib
- aldesleukin
- beclomethasone
- Filgrastim
- levetiracetam
- zarnestra
- sirolimus
- cyclosporine
- mycophenolate
- t cell depleted hematopoietic stem cells
- allogeneic lymphocytes
- alemtuzumab
- Anti-thymocyte Globulin (Rabbit)
- autologous umbilical cord blood
- cd45-depleted allogenic peripheral blood stem cell
- mesna
- rituximab
- haplo-identical hematopoietic stem cells
- cytarabine
- isotretinoin
- treosulfan
- +1 more
Phase 1 trials (15)
Other trials (2)
Organizations
Organization Involved with Phase 4 Indications (1)
Organization Involved with Phase 3 Indications (11)
Organization Involved with Phase 2 Indications (92)
- S*BIO
- Incyte
- Eisai
- Ambit Biosciences
- Celgene
- Bristol-Myers Squibb
- Amgen
- Astellas
- Genentech
- Genzyme
- Pfizer
- Aprea Therapeutics AB
- BioLite, Inc.
- INC Research
- Kura Oncology, Inc.
- Sensei Pharmaceuticals, Inc.
- Teva
- Nerviano Medical Sciences
- TetraLogic Pharmaceuticals
- Stemline Therapeutics, Inc.
- National Heart, Lung, and Blood Institute (NHLBI)
- Vastra Gotaland Region
- Nordic MDS Group
- Aarhus University
- University of Arizona
- Arbeitsgemeinschaft medikamentoese Tumortherapie
- Case Western Reserve University
- University of London
- Harvard University
- Temple University
- +62 more
Organization Involved with Phase 1 Indications (24)
- Seattle Genetics
- AstraZeneca
- Pharmacyclics
- Eli Lilly
- Bellicum Pharmaceuticals
- CTI BioPharma
- Erimos Pharmaceuticals
- JW Pharmaceutical
- Regimmune Inc.
- Boehringer Ingelheim
- National Institutes of Health (NIH)
- University of Pittsburgh
- AIDS Malignancy Consortium
- New York Medical College
- University of Maryland
- Wake Forest University
- University of California, Davis
- Loxo Oncology
- University of North Carolina at Chapel Hill
- University of Alabama, Birmingham
- Washington University in St. Louis
- Alex's Lemonade Stand Foundation
- Humanigen
- Newave Pharmaceutical Inc